Fig. 1
Chart depicting CRISPR/Cas9-based LOF screening strategy to identify molecular targets synthetically lethal with sunitinib treatment.
Fig. 1 | British Journal of Cancer
Chart depicting CRISPR/Cas9-based LOF screening strategy to identify molecular targets synthetically lethal with sunitinib treatment.
